Aditxt

Aditxt Earnings Yield

The Earnings Yield of Aditxt (ADTX) as of Nov 18, 2026 is -12,080.95 %. In the previous year, Earnings Yield was -9,975.99 % — a change of 21.10% (lower).

Earnings Yield

-12,080.95 %

YoY

21.10%

Last updated:

Earnings Yield of Aditxt is 2025 -12,080.95 % . Earnings Yield of Aditxt was 2024 -9,975.99 % . It decreases by 21.10% lower compared to the previous year.

The Aditxt Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-1,647.67 USD
Jan 1, 2019
-1,688.34 USD
Jan 1, 2020
-2,649.73 USD
Jan 1, 2021
-13,429.62 USD
Jan 1, 2022
-8,007.78 USD
Jan 1, 2023
-9,377.90 USD
Jan 1, 2024
-9,975.99 USD
Jan 1, 2025
-12,080.95 USD
The Aditxt Earnings Yield history
YEAREarnings YieldYoY
-12,080.95 %+21.10%
-9,975.99 %+6.38%
-9,377.90 %+17.11%
-8,007.78 %-40.37%
-13,429.62 %+406.83%
-2,649.73 %+56.94%
-1,688.34 %+2.47%
-1,647.67 %+2,571.00%
-61.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Earnings Yield of Aditxt is -12,080.95 % in 2025.

Earnings Yield of Aditxt changed from -9,975.99 % to -12,080.95 %, representing a 21.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Aditxt since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Aditxt with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aditxt

All Key Metrics — Aditxt